Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $5.00 price target on the stock.
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 [Yahoo! Finance]
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101